Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016661 · ClinicalTrials.gov registry record · Phase 2
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
A Phase 2 study, sponsored by AEON Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 466
- Enrollment target
NCT05016661 is a Phase 2 study that was terminated before completion, run by AEON Biopharma. The registered enrollment target is 466 participants.
The verdict
NCT05016661, a Phase 2 study, was terminated before completion, sponsored by AEON Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 466 participants
- Enrollment target
Study Summary
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll approximately 666 patients across approximately 65 sites in the United States, Canada and Australia from the Phase 2 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of ABP-450 utilizing the Company's novel injection paradigm.
Interventions
- DRUG ABP-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05016661
The ClinicalTrials.gov registry entry for NCT05016661 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEON Biopharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABP-450 is the first listed.
NCT05016661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05016661 about?
NCT05016661 is a clinical study titled "Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention". This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll approximately 666 patients across approximately 65 sites in the United States, Canada and Australia from the Phas...
What is the current status of trial NCT05016661?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 466 participants. The study started on 2021-10-19. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT05016661?
The interventions under investigation include: ABP-450 (DRUG).
Who is sponsoring clinical trial NCT05016661?
This trial is sponsored by AEON Biopharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.